rs144708625
Positions:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_001278116.2(L1CAM):c.396C>T(p.Ala132=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00042 in 1,203,587 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 122 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0012 ( 0 hom., 27 hem., cov: 21)
Exomes 𝑓: 0.00034 ( 0 hom. 95 hem. )
Consequence
L1CAM
NM_001278116.2 synonymous
NM_001278116.2 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -4.82
Genes affected
L1CAM (HGNC:6470): (L1 cell adhesion molecule) The protein encoded by this gene is an axonal glycoprotein belonging to the immunoglobulin supergene family. The ectodomain, consisting of several immunoglobulin-like domains and fibronectin-like repeats (type III), is linked via a single transmembrane sequence to a conserved cytoplasmic domain. This cell adhesion molecule plays an important role in nervous system development, including neuronal migration and differentiation. Mutations in the gene cause X-linked neurological syndromes known as CRASH (corpus callosum hypoplasia, retardation, aphasia, spastic paraplegia and hydrocephalus). Alternative splicing of this gene results in multiple transcript variants, some of which include an alternate exon that is considered to be specific to neurons. [provided by RefSeq, May 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BP6
Variant X-153872156-G-A is Benign according to our data. Variant chrX-153872156-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 197139.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-4.82 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00121 (133/109733) while in subpopulation AFR AF= 0.00371 (112/30211). AF 95% confidence interval is 0.00315. There are 0 homozygotes in gnomad4. There are 27 alleles in male gnomad4 subpopulation. Median coverage is 21. This position pass quality control queck.
BS2
High Hemizygotes in GnomAd4 at 27 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
L1CAM | NM_001278116.2 | c.396C>T | p.Ala132= | synonymous_variant | 5/29 | ENST00000370060.7 | NP_001265045.1 | |
L1CAM | NM_000425.5 | c.396C>T | p.Ala132= | synonymous_variant | 4/28 | NP_000416.1 | ||
L1CAM | NM_024003.3 | c.396C>T | p.Ala132= | synonymous_variant | 4/27 | NP_076493.1 | ||
L1CAM | NM_001143963.2 | c.381C>T | p.Ala127= | synonymous_variant | 3/26 | NP_001137435.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
L1CAM | ENST00000370060.7 | c.396C>T | p.Ala132= | synonymous_variant | 5/29 | 5 | NM_001278116.2 | ENSP00000359077 | A1 |
Frequencies
GnomAD3 genomes AF: 0.00122 AC: 134AN: 109682Hom.: 0 Cov.: 21 AF XY: 0.000844 AC XY: 27AN XY: 31998
GnomAD3 genomes
AF:
AC:
134
AN:
109682
Hom.:
Cov.:
21
AF XY:
AC XY:
27
AN XY:
31998
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000476 AC: 87AN: 182747Hom.: 0 AF XY: 0.000252 AC XY: 17AN XY: 67331
GnomAD3 exomes
AF:
AC:
87
AN:
182747
Hom.:
AF XY:
AC XY:
17
AN XY:
67331
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000340 AC: 372AN: 1093854Hom.: 0 Cov.: 30 AF XY: 0.000264 AC XY: 95AN XY: 359480
GnomAD4 exome
AF:
AC:
372
AN:
1093854
Hom.:
Cov.:
30
AF XY:
AC XY:
95
AN XY:
359480
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00121 AC: 133AN: 109733Hom.: 0 Cov.: 21 AF XY: 0.000842 AC XY: 27AN XY: 32059
GnomAD4 genome
AF:
AC:
133
AN:
109733
Hom.:
Cov.:
21
AF XY:
AC XY:
27
AN XY:
32059
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | May 14, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2024 | L1CAM: BP4, BP7, BS2 - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 29, 2017 | - - |
Spastic paraplegia Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 29, 2014 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 24, 2014 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at